Stentys, listed on NYSE Euronext, offers a platform that allows cardiologists to choose the appropriate stent size for patients with acute myocardial infarction or bifurcation lesions. Their self-apposing stents can adapt to different vessel diameters and continue to expand over time, preventing malapposition problems associated with conventional stents. Founded in 2006, Stentys focuses on mechanical improvements in stent design to provide pragmatic solutions for treating complex lesions in cardiovascular diseases. They are engaged in designing, developing, and marketing self-expanding stents for patients with acute myocardial infarction and other complex coronary diseases.